Kenneth H Shain MD

Hematology•Tampa, FL

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Associate Member Moffitt Cancer Center

Request appointment

12902 Usf Magnolia DrTampa, FL 33612
Book by Phone+1(218) 395-3265

Overview of Dr. Shain

Dr. Kenneth Shain is a hematologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from University of South Florida College of Medicine and has been in practice 20 years. He is one of 60 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Hematology. He has more than 100 publications and over 500 citings.

Education & Training

University of South Florida Morsani College of Medicine/Moffitt Cancer Center/Tampa General HospitalFellowship, Hematology and Medical Oncology, 2008 - 2011
University of South Florida MorsaniResidency, Internal Medicine, 2006 - 2008
University of South Florida College of MedicineClass of 2006

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2010 - 2028
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification HealtheLife and PowerChart, Cerner Corporation, 2014, 2016-2017
CMS Meaningful Use Stage 1 Certification PowerChart (Clinical), Cerner Corporation, 2014, 2016-2017
CMS Meaningful Use Stage 1 Certification PowerChart (CQM), Cerner Corporation, 2014, 2016-2017

Clinical Trials

Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma Start of enrollment: 2009 Jun 01
COMPLETED
PHASE1, PHASE2
Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma Start of enrollment: 2009 Jun 18
COMPLETED
PHASE2
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma
UNKNOWN
PHASE1, PHASE2

Publications & Presentations

PubMed

Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia.
Mahmoud R Gaballa, Kelley Julian, Aimaz Afrough, Doris K Hansen, Utkarsh Goel
Blood Advances. 2026-07-02
Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma.
Laura B Oswald, Xiaoyin Li, Lisa M Gudenkauf, Gabe De Avila, David Scheiber-Camoretti
Bone Marrow Transplantation. 2026-07-01
Product-Intrinsic NF-κB-Driven Transcriptional Programs Connote Durability of CAR-T Response in Multiple Myeloma.
Jerald D Noble, Barbara C Peixoto, Meghan A Menges, Julieta Abraham-Miranda, Constanza Savid-Frontera
Blood. 2026-06-11

Abstracts/Posters

Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...
Kenneth H. Shain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
Kenneth H. Shain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Composition of Immune Subpopulations Influence Multiple Myeloma Disease Progression
Kenneth H. Shain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Pharmacodynamical Modeling of Two-Way Synergistic Effect for High-Throughput Drug Combination Screening in an Ex Vivo Reconstruction of Bone Marrow Using Primary Multi...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018